176 related articles for article (PubMed ID: 35638454)
1. Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis.
Burns R; Niendorf K; Steinberg K; Mueller A; Ly I; Jordan JT; Plotkin SR; Hicks SR
Am J Med Genet A; 2022 Aug; 188(8):2413-2420. PubMed ID: 35638454
[TBL] [Abstract][Full Text] [Related]
2. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Plotkin SR; Messiaen L; Legius E; Pancza P; Avery RA; Blakeley JO; Babovic-Vuksanovic D; Ferner R; Fisher MJ; Friedman JM; Giovannini M; Gutmann DH; Hanemann CO; Kalamarides M; Kehrer-Sawatzki H; Korf BR; Mautner VF; MacCollin M; Papi L; Rauen KA; Riccardi V; Schorry E; Smith MJ; Stemmer-Rachamimov A; Stevenson DA; Ullrich NJ; Viskochil D; Wimmer K; Yohay K; ; Huson SM; Wolkenstein P; Evans DG
Genet Med; 2022 Sep; 24(9):1967-1977. PubMed ID: 35674741
[TBL] [Abstract][Full Text] [Related]
3. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.
Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A
J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Plotkin SR
Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis- and schwannomatosis-associated tumors: Approaches to genetic testing and counseling considerations.
Goetsch Weisman A; Weiss McQuaid S; Radtke HB; Stoll J; Brown B; Gomes A
Am J Med Genet A; 2023 Oct; 191(10):2467-2481. PubMed ID: 37485904
[TBL] [Abstract][Full Text] [Related]
6. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
[TBL] [Abstract][Full Text] [Related]
7. Schwannomatosis: a Realm Reborn: year one.
Planet M; Kalamarides M; Peyre M
Curr Opin Oncol; 2023 Nov; 35(6):550-557. PubMed ID: 37820090
[TBL] [Abstract][Full Text] [Related]
8. Schwannomatosis: the overlooked neurofibromatosis?
Koontz NA; Wiens AL; Agarwal A; Hingtgen CM; Emerson RE; Mosier KM
AJR Am J Roentgenol; 2013 Jun; 200(6):W646-53. PubMed ID: 23701098
[TBL] [Abstract][Full Text] [Related]
9. Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2-related schwannomatosis.
Halliday D; Emmanouil B; Evans DGR
Clin Genet; 2023 May; 103(5):540-552. PubMed ID: 36762955
[TBL] [Abstract][Full Text] [Related]
10. Distinctive low epidermal nerve fiber density in schwannomatosis patients provides a major parameter for diagnosis and differential diagnosis.
Farschtschi SC; Kluwe L; Schön G; Friedrich RE; Matschke J; Glatzel M; Weis J; Hagel C; Mautner VF
Brain Pathol; 2020 Mar; 30(2):386-391. PubMed ID: 31424590
[TBL] [Abstract][Full Text] [Related]
11. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
[TBL] [Abstract][Full Text] [Related]
12. What to know about schwannomatosis: a literature review.
Schraepen C; Donkersloot P; Duyvendak W; Plazier M; Put E; Roosen G; Vanvolsem S; Wissels M; Bamps S
Br J Neurosurg; 2022 Apr; 36(2):171-174. PubMed ID: 33263426
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
[TBL] [Abstract][Full Text] [Related]
14. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
[TBL] [Abstract][Full Text] [Related]
15. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.
Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S
Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060
[TBL] [Abstract][Full Text] [Related]
18. Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR;
Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649
[TBL] [Abstract][Full Text] [Related]
19. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.
Smith MJ; Kulkarni A; Rustad C; Bowers NL; Wallace AJ; Holder SE; Heiberg A; Ramsden RT; Evans DG
Am J Med Genet A; 2012 Jan; 158A(1):215-9. PubMed ID: 22105938
[TBL] [Abstract][Full Text] [Related]
20. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
